Waldschmidt, Johannes M.
Yee, Andrew J.
Vijaykumar, Tushara
Pinto, Ricardo A. http://orcid.org/0000-0002-9175-1357
Frede, Julia http://orcid.org/0000-0002-4380-9673
Anand, Praveen
Bianchi, Giada http://orcid.org/0000-0003-3673-0104
Guo, Guangwu
Potdar, Sayalee http://orcid.org/0000-0001-5390-1222
Seifer, Charles
Nair, Monica S.
Kokkalis, Antonis http://orcid.org/0000-0001-7779-0600
Kloeber, Jake A. http://orcid.org/0000-0002-6646-564X
Shapiro, Samantha
Budano, Lillian
Mann, Mason
Friedman, Robb
Lipe, Brea
Campagnaro, Erica
O’Donnell, Elizabeth K.
Zhang, Cheng-Zhong
Laubach, Jacob P. http://orcid.org/0000-0001-7565-2052
Munshi, Nikhil C. http://orcid.org/0000-0002-7344-9795
Richardson, Paul G. http://orcid.org/0000-0002-7426-8865
Anderson, Kenneth C. http://orcid.org/0000-0002-6418-0886
Raje, Noopur S.
Knoechel, Birgit http://orcid.org/0000-0002-8040-0535
Lohr, Jens G. http://orcid.org/0000-0003-3486-2445
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (391926441)
International Myeloma Society
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA191091, K08CA191026)
V Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Anna Fuller Fund
Article History
Received: 20 September 2021
Revised: 24 November 2021
Accepted: 2 December 2021
First Online: 13 January 2022
Competing interests
: No disclosures are related to this publication. JMW: Advisory boards of Janssen and Sanofi. AJY: Advisory boards of Adaptive, Amgen, Bristol-Myers Squibb, GSK, Janssen, Karyopharm, Oncopeptides, Regeneron, Sanofi and Takeda. Clinical trial support from Adaptive, Amgen, BMS, Bristol-Myers Squibb, Janssen and Takeda. BL: Research funding from Amgen and Cellectar. Advisory boards of Bristol-Myers Squibb, Janssen, and GlaxoSmithKline. C-ZZ: Co-founder, advisor, and equity holder of Pillar BioSciences. PGR: Advisory boards of AbbVie, AstraZeneca, GSK, Bristol-Myers Squibb, Oncopeptides, Celgene, Takeda, and Karyopharm. Advisory boards of Oncopeptides, Janssen, Sanofi, and Secura Bio. KCA: Advisory boards of Janssen, Amgen, Pfizer, AstraZeneca, Precision Biosciences, Bristol-Myers Squibb, Mana, Starton, Window during the conduct of the study; other support from C4 Therapeutics, Oncopep, Raqia; and other support from NextRNA outside the submitted work. NSR: Advisory boards of Amgen, Bristol-Myers Squibb, Janssen, Sanofi, Takeda, AstraZeneca, GSK, Pfizer, Caribou, Immuneel and C4 Therapeutics. Research funding from BluebirdBio. JGL: Consultant for T2 Biosystems outside the submitted work. Research funding from Bristol-Myers Squibb, Celgene. All other authors declare no conflicts of interest.